A study commissioned by the Campaign for Sustainable Rx Pricing revealed that drugmakers spend an average of 22% of revenue on research and development, reinforcing the industry's own estimate of 20%.
The National Health Service England and Biogen have entered an access agreement to fund Biogen's spinal muscular atrophy drug Spinraza for a limited period to evaluate its efficacy. Details regarding the amount to be paid for the drug, which costs $750,000 for the first year and $375,000 per year thereafter in the US, weren't disclosed by NHS England.
Onconova Therapeutics and HanX Biopharmaceuticals agreed to work together to develop and market products, including rigosertib, in China. Under the terms of the agreement, Onconova will get $6 million upfront, plus milestone payments and royalties.
Sosei Heptares has received a milestone payment of $3 million after Pfizer chose the first preclinical small-molecule drug targeted at G-protein coupled receptors created under the collaboration for development.
Optimize your clinical trial program with the AWS Cloud Clinical trials bring a variety of challenges, including costs, delays and recruitment shortfalls. These challenges can be overcome with a modernized trial program that takes advantage of cloud technology, AI and machine learning. Learn more with this infographic.
The NIH's All of Us precision medicine research program has launched an interactive data browser that allows members of the public and researchers to access information about people who have participated in the program to date. The summary data includes EHR information, physical measurements gathered from the program's partner sites and basic demographic and lifestyle information.
AbbVie settled a patent dispute with Boehringer Ingelheim over a biosimilar version of AbbVie's Humira, or adalimumab, with Boehringer agreeing to delay US introduction until July 2023. Amgen, Fresenius Kabi, Mylan, Samsung Bioepis, Pfizer and Novartis unit Sandoz have reached similar patent settlements with AbbVie.
AstraZeneca's Qternmet XR, a combination therapy that contains dapagliflozin, metformin and saxagliptin, has been approved by the FDA as an adjunct to diet and exercise for patients with type 2 diabetes. The approval was based on the results of two Phase III trials, both of which showed significant HbA1C reductions among those given the drug.
The global need for chemotherapy treatment is estimated to increase 53% by 2040, and more cancer physicians will be needed, according to a study published in The Lancet Oncology. "Strategies are urgently needed to equip the global health workforce to enable safe treatment of current and future patients," said Brooke Wilson, the study's lead author.
How can we advance discovery science for public health impact? Gary Gibbons, MD, Director of the National Heart, Lung and Blood Institute (NHLB) at the National Institutes of Health, will address that question and more as he delivers the keynote address at the DIA 2019 Global Annual Meeting in San Diego. Gain valuable skills and insights, discover the latest breakthroughs, and network with more than 7,000 peers and colleagues at the largest life-sciences event of its kind! With more than 250 sessions, 13 core interest areas, and 450 exhibitors, there's something for everyone - check out our program today!
Shake up your mental processes
Need a new way of thinking or just looking to stimulate your creativity? DIA has a solution! Take your learning to a new level by attending one of our many life sciences events, held around the globe. Check out our upcoming, can't-miss meetings for health care and life sciences professionals:
